The U.S. Food and Drug Administration is fundamentally changing its approach to new drug approvals, announcing that a single rigorous clinical trial, backed by strong confirmatory evidence, will now be its default standard. This move abandons a decades-long expectation that required two successful pivotal studies, aiming to accelerate patient access to new therapies without compromising scientific rigor.
The policy shift, detailed by FDA Commissioner Marty Makary and other senior officials, is among the most significant regulatory changes in recent history. It is grounded in the argument that modern drug development, supported by advanced biology, biomarker data, and sophisticated trial designs, has outgrown a rigid two-trial requirement. "In this setting, over-reliance on two trials no longer makes sense," officials stated, noting that powerful alternative methods now exist to confirm a product's benefit. They anticipate this change will spur a surge in drug development.
Historically, the two-trial standard served as a safeguard to minimize the chance that a positive result was a statistical fluke. However, the FDA has held statutory authority since 1997 to approve drugs based on one adequate and well-controlled study plus confirmatory evidence. This evidence can include mechanistic data, real-world evidence, or results in related conditions. Under the new paradigm, the focus will shift from the number of trials to the quality of a single study. Reviewers will concentrate on factors like the magnitude of treatment effect, statistical power, and biological plausibility.
Experts like former FDA drug center director Dr. Janet Woodcock support the scientific rationale, noting the agency has already successfully used such flexibility for oncology and rare disease drugs. "The scientific point is well taken that as we move toward greater understanding of biology and disease we don't need to do two trials all the time," Woodcock said. She indicated the greater impact may be felt for more common conditions, which historically faced the two-study benchmark. Makary and colleagues reject notions that the policy weakens standards, arguing that two poorly designed trials are less reliable than one meticulously executed study.
The change is part of a broader initiative by the current FDA leadership to streamline reviews. The agency expects this updated framework to make the development process more efficient, ultimately bringing a wider range of new treatments to patients sooner while maintaining a commitment to robust evidence of safety and efficacy.